Opko Health, Inc. (NASDAQ:OPK) received a $20.00 price objective from research analysts at Cantor Fitzgerald in a report released on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 190.70% from the stock’s current price.

A number of other analysts have also recently issued reports on the company. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research report on Friday, July 21st. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 price objective on shares of Opko Health in a research report on Friday, June 16th. BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. J P Morgan Chase & Co cut Opko Health from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $12.00 to $7.00 in a research report on Thursday, September 14th. Finally, Barrington Research boosted their price objective on Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $13.97.

Opko Health (OPK) traded up 1.03% during mid-day trading on Thursday, hitting $6.88. 4,536,255 shares of the stock were exchanged. The company’s market cap is $3.85 billion. Opko Health has a one year low of $5.85 and a one year high of $12.15. The company has a 50-day moving average price of $6.53 and a 200-day moving average price of $6.73.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company had revenue of $314.20 million during the quarter, compared to analyst estimates of $322.64 million. During the same period in the previous year, the company earned $0.02 earnings per share. The company’s quarterly revenue was down 12.0% compared to the same quarter last year. On average, analysts predict that Opko Health will post ($0.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/12/opko-health-inc-opk-pt-set-at-20-00-by-cantor-fitzgerald.html.

In other news, CEO Phillip Md Et Al Frost purchased 12,600 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were acquired at an average price of $6.16 per share, with a total value of $77,616.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $18,904,738.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought 938,400 shares of company stock worth $5,745,521 in the last 90 days. Company insiders own 40.19% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Credit Suisse AG lifted its stake in shares of Opko Health by 122.0% during the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after acquiring an additional 410,445 shares during the period. State Street Corp lifted its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD lifted its stake in Opko Health by 14.8% in the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock valued at $910,000 after buying an additional 17,458 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in Opko Health in the first quarter valued at about $4,450,000. Finally, State Board of Administration of Florida Retirement System lifted its stake in Opko Health by 7.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock valued at $2,634,000 after buying an additional 27,940 shares during the period. 22.46% of the stock is currently owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.